If you would like more information about the profile please click
. You will be directed to a new page where you will need
to provide some information about yourself/your business cooperation needs and submit
your expression of interest in the profile . A Network Partner will then contact
you to discuss your interest in greater detail.
Spanish researchers working in analytical chemistry and neurology have developed a new way of differentiating between stroke subtypes, diseases or brain damages through biomarkers from the central nervous system (CNS), by analyzing non-invasive samples (nasal exudate), in a quick, simple and painless way. Companies in the biotechnology and pharmacy fields, as well as in medicine and clinical diagnosis, are sought to develop applications of the described invention under license agreements.
The current diagnostic evaluation of acute stroke depends largely on neuroimaging techniques, such as computed tomography (CT) and brain magnetic resonance imaging (MRI). Although neuroimaging provides valuable diagnostic information, it is not always available, it requires specific infrastructure, considerable resources and specialized personnel, and sometimes it is not possible to do it on time. Other current solutions involve complex, invasive and slow procedures on the patient.
Researchers from a Spanish university working in Analytical Chemistry and Neurology provide new methods and panels to differentiate between stroke subtypes, diseases or brain damage through biomarkers from the central nervous system (CNS), by analyzing samples of nasal exudate. The existence of a cerebral lymphatic drainage through the cribriform plate of the ethmoid bone could imply the presence in the nasal secretion of biomarkers that warn of the occurrence of certain cerebral episodes, neurological diseases or CNS events.
The methods include analyzing a biological sample of nasal exudate to determine the concentration of one or more biomarkers, and then correlating it with the occurrence of a cerebral episode. The panels comprise a plurality of biomarkers that come from a sample of nasal exudate from the subject. The analytical procedures comprise means for non-invasive extraction of the sample and a detection system.
The invention is applicable in the biotechnology and pharmacy fields, as well as in medicine and clinical diagnosis. It is also of great interest for the search for biomarkers that allow the study of other diseases such as Alzheimer's or Parkinson's or processes such as aging, closely related to failures in the drainage of proteins or other products of brain metabolism.
The researchers would like to reach license agreements with companies operating in the above-mentioned fields with the aim to develop applications of the described technology.
• The biomarkers are quantified from the CNS in nasal exudate, which contains CNS information thanks to cerebral lymphatic drainage that allows species to pass through the cribriform plate to the nasal mucosa. Through this invention it is shown for the first time that nasal exudate samples are suitable for obtaining information from the CNS. Since there is high anatomical proximity, the biomarker dilution is not high.
• Nasal exudate is easy to obtain from a patient through quick, simple, painless and minimally invasive extraction processes. It is not necessary therefore that the subject is at the hospital. In addition, qualified personnel are not required for sampling (unlike what happens with, for example, a lumbar puncture to extract cerebrospinal fluid).
• The invention also allows rapid therapeutic and logistic decisions.
• It allows differentiating between ischemic and haemorrhagic strokes.
• Metals or proteins can be used as biomarkers. The use of metallic biomarkers avoids the use of biological reagents and the performance of immunoassays, which normally require a longer procedure.
• The invention provides techniques and technology that offer homogeneous and extraordinarily reliable results.
Technology validated in a relevant environment (i.e. the basic technological components have been integrated together with real elements to be analysed in a simulated environment. There is a “high fidelity” prototype).
Spanish patent applied for.
Type of partner sought: industry.
Specific area of activity of the partner: companies working in the biotechnology and pharmacy fields, as well as in medicine and clinical diagnosis.
Task to be performed: development of applications of the described invention.